{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T22:20:52Z","timestamp":1794694852556,"version":"4.9.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP25K10062"],"award-info":[{"award-number":["JP25K10062"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16148-2","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T10:44:35Z","timestamp":1778237075000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Severe anemia as a risk factor in Japanese patients with ovarian cancer receiving olaparib: a retrospective study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5175-1413","authenticated-orcid":false,"given":"Kenta","family":"Yamaoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Kume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Hirabatake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutaka","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Muroi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"16148_CR1","unstructured":"Cancer statistics in Japan. 2022. https:\/\/ganjoho.jp\/public\/qa_links\/report\/statistics\/2022_en.html. Accessed 1 May 2025."},{"key":"16148_CR2","doi-asserted-by":"publisher","unstructured":"Karam A, Ledermann JA, Kim JW, Sehouli J, Lu K, Gourley C et al. Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: first-line interventions. Ann Oncol. 2017;28:711-7. https:\/\/doi.org\/10.1093\/annonc\/mdx011.","DOI":"10.1093\/annonc\/mdx011"},{"key":"16148_CR3","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484\u201396. https:\/\/doi.org\/10.1056\/NEJMoa1103799.","journal-title":"N Engl J Med"},{"key":"16148_CR4","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.3390\/ijms20143390","volume":"20","author":"M Garutti","year":"2019","unstructured":"Garutti M, Pelizzari G, Bartoletti M, Malfatti MC, Gerratana L, Tell G, et al. Platinum salts in patients with breast cancer: a focus on predictive factors. Int J Mol Sci. 2019;20:3390. https:\/\/doi.org\/10.3390\/ijms20143390.","journal-title":"Int J Mol Sci"},{"key":"16148_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(02)00847-1.","author":"M Harries","year":"2002","unstructured":"Harries M, Gore M. Part II: Chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol. 2002;3:537-45. https:\/\/doi.org\/10.1016\/s1470-2045(02)00847-1."},{"key":"16148_CR6","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473\u201383. https:\/\/doi.org\/10.1056\/NEJMoa1104390.","journal-title":"N Engl J Med"},{"key":"16148_CR7","doi-asserted-by":"publisher","first-page":"7519","DOI":"10.1038\/s41598-024-57367-6","volume":"14","author":"T Motonari","year":"2024","unstructured":"Motonari T, Yoshino Y, Haruta M, Endo S, Sasaki S, Miyashita M, et al. Evaluating homologous recombination activity in tissues to predict the risk of hereditary breast and ovarian cancer and olaparib sensitivity. Sci Rep. 2024;14:7519. https:\/\/doi.org\/10.1038\/s41598-024-57367-6.","journal-title":"Sci Rep"},{"key":"16148_CR8","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","volume":"31","author":"RE Miller","year":"2020","unstructured":"Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol. 2020;31:1606\u201322. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2102.","journal-title":"Ann Oncol"},{"key":"16148_CR9","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa1810858.","journal-title":"N Engl J Med"},{"key":"16148_CR10","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, P\u00e9rol D, Gonz\u00e1lez-Mart\u00edn A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1911361.","journal-title":"N Engl J Med"},{"key":"16148_CR11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s11523-021-00838-x","volume":"16","author":"YS Lu","year":"2021","unstructured":"Lu YS, Yeo W, Yap YS, Park YH, Tamura K, Li H, et al. An overview of the treatment efficacy and side effect profile of pharmacological therapies in Asian patients with breast cancer. Target Oncol. 2021;16:701\u201341. https:\/\/doi.org\/10.1007\/s11523-021-00838-x.","journal-title":"Target Oncol"},{"key":"16148_CR12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/1471-2407-9-249","volume":"9","author":"H Zhang","year":"2009","unstructured":"Zhang H, Dong B, Lu JJ, Yao X, Zhang S, Dai B, et al. Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study. BMC Cancer. 2009;9:249. https:\/\/doi.org\/10.1186\/1471-2407-9-249.","journal-title":"BMC Cancer"},{"key":"16148_CR13","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1200\/JCO.21.02628","volume":"10","author":"T Yoshino","year":"2022","unstructured":"Yoshino T, Oki E, Misumi T, Kotaka M, Manaka D, Eto T, et al. Final analysis of 3 versus 6 months of adjuvant oxaliplatin and fluoropyrimidine-based therapy in patients with Stage III colon cancer: The randomized Phase III ACHIEVE trial. J Clin Oncol Oct. 2022;10:40:3419\u201329. https:\/\/doi.org\/10.1200\/JCO.21.02628.","journal-title":"J Clin Oncol Oct"},{"key":"16148_CR14","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","volume":"29","author":"A Grothey","year":"2018","unstructured":"Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, et al. Duration of adjuvant chemotherapy for Stage III colon cancer. N Engl J Med Mar. 2018;29:378:1177\u201388. https:\/\/doi.org\/10.1056\/NEJMoa1713709.","journal-title":"N Engl J Med Mar"},{"key":"16148_CR15","doi-asserted-by":"publisher","first-page":"883","DOI":"10.21873\/anticanres.16231","volume":"43","author":"C Shiraishi","year":"2023","unstructured":"Shiraishi C, Hirai T, Ogura T, Iwamoto T. Analysis of clinical factors in olaparib-related anemia using adverse drug event reporting databases. Anticancer Res. 2023;43:883\u201391. https:\/\/doi.org\/10.21873\/anticanres.16231.","journal-title":"Anticancer Res"},{"key":"16148_CR16","doi-asserted-by":"publisher","first-page":"e34123","DOI":"10.1097\/MD.0000000000034123","volume":"102","author":"C Shiraishi","year":"2023","unstructured":"Shiraishi C, Hirai T, Kaneda M, Okamoto A, Kato H, Tanaka K, et al. Factors for the development of anemia in patients with newly introduced olaparib: a retrospective case-control study. Med (Baltim). 2023;102:e34123. https:\/\/doi.org\/10.1097\/MD.0000000000034123.","journal-title":"Med (Baltim)"},{"key":"16148_CR17","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.3390\/life12091355","volume":"12","author":"K Yamaoka","year":"2022","unstructured":"Yamaoka K, Fujiwara M, Uchida M, Uesawa Y, Muroi N, Shimizu T. Comprehensive analysis of adverse events induced by PARP inhibitors using JADER and time to onset. Life (Basel). 2022;12:1355. https:\/\/doi.org\/10.3390\/life12091355.","journal-title":"Life (Basel)"},{"key":"16148_CR18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00280-023-04514-x","volume":"91","author":"J Baum","year":"2023","unstructured":"Baum J, Zickler D, Bolbrinker J, Richter R, Braicu EI, Grabowski J, et al. Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis. Cancer Chemother Pharmacol. 2023;91:325\u201330. https:\/\/doi.org\/10.1007\/s00280-023-04514-x.","journal-title":"Cancer Chemother Pharmacol"},{"key":"16148_CR19","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s40262-019-00754-4","volume":"58","author":"C Rolfo","year":"2019","unstructured":"Rolfo C, de Vos-Geelen J, Isambert N, Molife LR, Schellens JHM, De Gr\u00e8ve J, et al. Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and renal impairment. Clin Pharmacokinet. 2019;58:1165\u201374. https:\/\/doi.org\/10.1007\/s40262-019-00754-4.","journal-title":"Clin Pharmacokinet"},{"key":"16148_CR20","doi-asserted-by":"publisher","first-page":"851246","DOI":"10.3389\/fphar.2022.851246","volume":"13","author":"X Tian","year":"2022","unstructured":"Tian X, Chen L, Gai D, He S, Jiang X, Zhang N. Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS. Front Pharmacol. 2022;13:851246. https:\/\/doi.org\/10.3389\/fphar.2022.851246.","journal-title":"Front Pharmacol"},{"key":"16148_CR21","doi-asserted-by":"publisher","first-page":"898150","DOI":"10.3389\/fonc.2022.898150","volume":"12","author":"R Tashiro","year":"2022","unstructured":"Tashiro R, Kawazoe H, Mamishin K, Seto K, Udagawa R, Saito Y, et al. Patient-associated risk factors for severe anemia in patients with advanced ovarian or breast cancer receiving olaparib monotherapy: a multicenter retrospective study. Front Oncol. 2022;12:898150. https:\/\/doi.org\/10.3389\/fonc.2022.898150.","journal-title":"Front Oncol"},{"key":"16148_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","volume":"95","author":"AN Gordon","year":"2004","unstructured":"Gordon AN, Tonda M, Sun S, Rackoff W. Doxil Study 30\u201349 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95:1\u20138. https:\/\/doi.org\/10.1016\/j.ygyno.2004.07.011.","journal-title":"Gynecol Oncol"},{"key":"16148_CR23","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"19","author":"AN Gordon","year":"2001","unstructured":"Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312\u201322. https:\/\/doi.org\/10.1200\/JCO.2001.19.14.3312.","journal-title":"J Clin Oncol"},{"key":"16148_CR24","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1200\/JCO.2006.06.0913","volume":"54","author":"A Gabizon","year":"1994","unstructured":"Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol-coated liposomes. Cancer Res. 1994;54:987\u201392. https:\/\/doi.org\/10.1200\/JCO.2006.06.0913.","journal-title":"Cancer Res"},{"key":"16148_CR25","doi-asserted-by":"publisher","first-page":"898146","DOI":"10.1155\/2013\/898146","volume":"2013","author":"C Pisano","year":"2013","unstructured":"Pisano C, Cecere SC, Di Napoli M, Cavaliere C, Tambaro R, Facchini G, et al. Clinical trials with pegylated liposomal doxorubicin in the treatment of ovarian cancer. J Drug Deliv. 2013;2013:898146. https:\/\/doi.org\/10.1155\/2013\/898146.","journal-title":"J Drug Deliv"},{"key":"16148_CR26","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","volume":"24","author":"J Pfisterer","year":"2006","unstructured":"Pfisterer J, Plante M, Vergote I, Du Bois A, Hirte H, Lacave AJ, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24:4699\u2013707.","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"16148_CR27","doi-asserted-by":"publisher","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","volume":"17","author":"E Mini","year":"2006","unstructured":"Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol. 2006;17(Suppl 5):v7\u201312. https:\/\/doi.org\/10.1093\/annonc\/mdj941.","journal-title":"Ann Oncol"},{"key":"16148_CR28","doi-asserted-by":"publisher","first-page":"CD006910","DOI":"10.1002\/14651858.CD006910.pub3","volume":"7","author":"R Newhouse","year":"2023","unstructured":"Newhouse R, Nelissen E, El-Shakankery KH, Rogozi\u0144ska E, Bain E, Veiga S, et al. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database Syst Rev. 2023;7:CD006910. https:\/\/doi.org\/10.1002\/14651858.CD006910.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"16148_CR29","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/jog.14558","volume":"47","author":"Y Takahashi","year":"2021","unstructured":"Takahashi Y, Takei Y, Machida S, Taneichi A, Takahashi S, Yoshiba T, et al. Efficacy and toxicity of pegylated liposomal doxorubicin as therapy for recurrent ovarian cancer in relation to the number of previous chemotherapy regimens: comparison with gemcitabine. J Obstet Gynaecol Res. 2021;47:551\u20139. https:\/\/doi.org\/10.1111\/jog.14558.","journal-title":"J Obstet Gynaecol Res"},{"key":"16148_CR30","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1002\/cpt.1338","volume":"105","author":"D Zhou","year":"2019","unstructured":"Zhou D, Li J, Learoyd M, Bui K, Berges A, Milenkova T, et al. Efficacy and safety exposure-response analyses of olaparib capsule and tablet formulations in oncology patients. Clin Pharmacol Ther. 2019;105:1492\u2013500. https:\/\/doi.org\/10.1002\/cpt.1338.","journal-title":"Clin Pharmacol Ther"},{"key":"16148_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2147\/CLEP.S89480","volume":"8","author":"H Xu","year":"2016","unstructured":"Xu H, Xu L, Page JH, Cannavale K, Sattayapiwat O, Rodriguez R, et al. Incidence of anemia in patients diagnosed with solid tumors receiving chemotherapy, 2010\u20132013. Clin Epidemiol. 2016;8:61\u201371. https:\/\/doi.org\/10.2147\/CLEP.S89480.","journal-title":"Clin Epidemiol"},{"key":"16148_CR32","doi-asserted-by":"publisher","first-page":"447","DOI":"10.21873\/cdp.10346","volume":"4","author":"H Inui","year":"2024","unstructured":"Inui H, Sato M, Yoshida H. Age is a risk factor for olaparib dose modification and discontinuation in patients with ovarian cancer. Cancer Diagn Progn. 2024;4:447\u201353. https:\/\/doi.org\/10.21873\/cdp.10346.","journal-title":"Cancer Diagn Progn"},{"issue":"6","key":"16148_CR33","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/aje\/kwk052","volume":"165","author":"E Vittinghoff","year":"2007","unstructured":"Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007;165(6):710\u20138. https:\/\/doi.org\/10.1093\/aje\/kwk052.","journal-title":"Am J Epidemiol"},{"issue":"7589","key":"16148_CR34","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1136\/bmj.39070.527986.68","volume":"334","author":"P Glasziou","year":"2007","unstructured":"Glasziou P, Chalmers I, Rawlins M, McCulloch P. When are randomised trials unnecessary? Picking signal from noise. BMJ. 2007;334(7589):349\u201351. https:\/\/doi.org\/10.1136\/bmj.39070.527986.68.","journal-title":"BMJ"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16148-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16148-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16148-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T05:26:05Z","timestamp":1782883565000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16148-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16148"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16148-2","relation":{"references":[{"id-type":"doi","id":"10.1016\/s1470-2045(02)00847-1","asserted-by":"subject"}],"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8806671\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involving human participants was reviewed and approved by the Institutional Review Board, Kobe City Medical Center General Hospital, Kobe, Japan (Approval no: zn230808, July 28, 2023). The requirement for informed consent was waived owing to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"796"}}